MPL突变和可触及的脾肿大是原发性血小板增多症纤维化进展的独立危险因素。 - Suppr

Suppr

超能文献

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.

作者信息

Haider M, Elala Y C, Gangat N, Hanson C A, Tefferi A

机构信息

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2016 Oct 21;6(10):e487. doi: 10.1038/bcj.2016.98.

DOI:10.1038/bcj.2016.98

PMID:27768091

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5098266/

Abstract

摘要

相似文献

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.MPL突变和可触及的脾肿大是原发性血小板增多症纤维化进展的独立危险因素。

Blood Cancer J. 2016 Oct 21;6(10):e487. doi: 10.1038/bcj.2016.98.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.MPL 突变的原发性血小板增多症：形态学再评估

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3.

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.原发性血小板增多症和原发性骨髓纤维化的突变状态决定临床结局。

Haematologica. 2016 Apr;101(4):e129-32. doi: 10.3324/haematol.2015.138958. Epub 2016 Jan 14.

Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.通过等位基因特异性聚合酶链反应鉴定原发性骨髓纤维化和原发性血小板增多症患者中的MPL W515L/K突变。

Acta Haematol. 2009;121(4):221-2. doi: 10.1159/000224333. Epub 2009 Jun 10.

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.CALR 突变、MPL 突变和三阴性可识别原发性骨髓纤维化中血管风险最低的患者。

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.JAK2（V617F）等位基因负荷可将原发性血小板增多症与一部分纤维化前期原发性骨髓纤维化区分开来。

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

Somatic mutations of calreticulin in myeloproliferative neoplasms.髓系增殖性肿瘤中的钙网织蛋白体细胞突变。

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.由 MPLSer505Asn 引起的遗传性血小板增多症与高血栓风险、脾肿大和向骨髓纤维化进展有关。

Haematologica. 2010 Jan;95(1):65-70. doi: 10.3324/haematol.2009.007542. Epub 2009 Aug 27.

Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.对原发性骨髓纤维化和特发性血小板增多症中 MPL 突变的筛查：在 MPLW515L 阳性血小板中 Mpl 表达正常，并且不存在组成性 STAT3 和 STAT5 激活。

Eur J Haematol. 2010 May;84(5):398-405. doi: 10.1111/j.1600-0609.2010.01421.x. Epub 2010 Jan 22.

Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.骨髓增殖性肿瘤 2012：约翰·M·班尼特 80 岁生日演讲。

Leuk Res. 2012 Dec;36(12):1481-9. doi: 10.1016/j.leukres.2012.08.011. Epub 2012 Aug 21.

引用本文的文献

One thousand patients with essential thrombocythemia: the Mayo Clinic experience.一千例原发性血小板增多症患者：梅奥诊所的经验。

Blood Cancer J. 2024 Jan 18;14(1):11. doi: 10.1038/s41408-023-00972-x.

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.一千例原发性血小板增多症患者：佛罗伦萨-CRIMM 研究经验。

Blood Cancer J. 2024 Jan 18;14(1):10. doi: 10.1038/s41408-023-00968-7.

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective study.原发性血小板增多症进展至原发性血小板增多症后骨髓纤维化早期预测模型的开发与验证：一项多中心回顾性研究

EClinicalMedicine. 2023 Dec 14;67:102378. doi: 10.1016/j.eclinm.2023.102378. eCollection 2024 Jan.

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.迈向个体化定义费城阴性骨髓增殖性肿瘤的预后。

Curr Hematol Malig Rep. 2022 Oct;17(5):127-139. doi: 10.1007/s11899-022-00672-6. Epub 2022 Sep 1.

Relationship between disease biology and clinical phenotype in myeloproliferative neoplasms.骨髓增殖性肿瘤中疾病生物学与临床表型的关系。

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000207. eCollection 2019 Jun.

The new WHO classification for essential thrombocythemia calls for revision of available evidences.新的世界卫生组织原发性血小板增多症分类要求修订现有证据。

Blood Cancer J. 2020 Feb 25;10(2):22. doi: 10.1038/s41408-020-0290-9.

Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.费城阴性骨髓增殖性肿瘤：下一代测序时代的实验室检测。

Curr Hematol Malig Rep. 2019 Oct;14(5):376-385. doi: 10.1007/s11899-019-00534-8.

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.真性红细胞增多症、特发性血小板增多症和原发性骨髓纤维化的分析研究系统评价及 JAK2、CALR 和 MPL 突变频率的荟萃分析：2000-2018 年。

BMC Cancer. 2019 Jun 17;19(1):590. doi: 10.1186/s12885-019-5764-4.

MPL-mutated essential thrombocythemia: a morphologic reappraisal.MPL 突变的原发性血小板增多症：形态学再评估

Blood Cancer J. 2018 Nov 20;8(12):121. doi: 10.1038/s41408-018-0159-3.

Essential thrombocythemia treatment algorithm 2018.2018 年原发性血小板增多症治疗算法

Blood Cancer J. 2018 Jan 10;8(1):2. doi: 10.1038/s41408-017-0041-8.

本文引用的文献

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.世界卫生组织真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化诊断标准的修订理由及拟议更改

Blood Cancer J. 2015 Aug 14;5(8):e337. doi: 10.1038/bcj.2015.64.

Myeloproliferative neoplasms: Morphology and clinical practice.骨髓增殖性肿瘤：形态学与临床实践。

Am J Hematol. 2016 Jun;91(4):430-3. doi: 10.1002/ajh.24288.

Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.真性红细胞增多症和原发性血小板增多症中的原始细胞转化和纤维化进展：发病率及危险因素的文献综述

Blood Cancer J. 2015 Nov 13;5(11):e366. doi: 10.1038/bcj.2015.95.

Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.原发性血小板增多症和真性红细胞增多症：聚焦临床实践。

Mayo Clin Proc. 2015 Sep;90(9):1283-93. doi: 10.1016/j.mayocp.2015.05.014.

Myeloproliferative Neoplasms: A Contemporary Review.骨髓增殖性肿瘤：当代综述。

JAMA Oncol. 2015 Apr;1(1):97-105. doi: 10.1001/jamaoncol.2015.89.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.分子注释的原发性血小板增多症、真性红细胞增多症和骨髓纤维化的长期生存及原始细胞转化

Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.形态学准确诊断对原发性血小板增多症的生存和疾病进展有显著影响：一项国际研究。

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.世界卫生组织（WHO）髓系肿瘤和急性白血病分类的2008年修订版：基本原理及重要变化

Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化的诊断标准建议：骨髓纤维化研究与治疗国际工作组的共识声明

Leukemia. 2008 Feb;22(2):437-8. doi: 10.1038/sj.leu.2404914. Epub 2007 Aug 30.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验